Skip to main content

Table 1 Clinical data of individuals included in cohort I

From: Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers

 

NC, n = 42

AD, n = 30

Age (years)

74 ± 6

74 ± 7a

Females (%)

69

70

APOEε4 carriers (%)

38

70

ADAS-Cog (score)

1.88 ± 1.70

8.67 ± 1.90***a

AQT (score)

63.24 ± 10.36

110.18 ± 46.72***a

MMSE (score)

29.19 ± 0.83

19.50 ± 4.27***a

CRP (mg/l)

1.75 ± 1.59

6.94 ± 13.12*a

CSF Aβ40 (pg/ml)

6759.52 ± 1906.93

6452.66 ± 1675.20a

CSF Aβ42 (pg/ml)

791.67 ± 289.29

386.70 ± 110.29***a

CSF p-tau (pg/ml)

45.61 ± 18.16

120.40 ± 41.24***a

CSF t-tau (pg/ml)

341.53 ± 106.23

621.81 ± 207.42***a

Q-albumin

6.75 ± 3.80

6.80 ± 2.54a

  1. amyloid beta, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale-Cognitive Subscale, APOE4 apolipoprotein 4, AQT A Quick Test, CRP C-reactive protein, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, NC non-demented control, p-tau phosphorylated tau, t-tau total tau
  2. aData were analysed using either Student’s t-test or Mann-Whitney U-test, and values are presented as mean value ± SD
  3. *Significant at p ≤ 0.05 level
  4. **Significant at p ≤ 0.01 level
  5. ***Significant at p ≤ 0.001 level